


An ordinary man living an extraordinary lung cancer story.



Case report of a 66-year-old patient with stage IV non-squamous undifferentiated NSCLC & **liver metastases.**
ECOG PS 1



TECENTRIQ
atezolizumab

Tecentriq, in combination with Avastin, paclitaxel and carboplatin, is indicated for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.

1L - mNSCLC

TECENTRIQ
+ AVASTIN
+ CARBOPLATIN
+ PACLITAXEL

*All medical and treatment details are from one IMpower 150 clinical trial patient. The name and personal details of the patient have been changed to protect patient confidentiality.

MEDICAL HISTORY

Arteriosclerosis

Former smoker
1 pack/day for 45 years

DIAGNOSIS | 09.2015

LESIONS



Liver



Brain



Lymph node

NEGATIVE MUTATIONS

EGFR | ALK
KRAS | ROS1
BRAF | HER2
MET-amp

PD-L1 IHC:
TC = 20%
IC = 15%



TREATMENT | 12.2015



Whole brain radiation for single brain lesion

Enrolled in clinical trial


01.2016
IMpower150
Randomised to Arm B

TECENTRIQ
+ AVASTIN
+ CARBOPLATIN
+ PACLITAXEL

4 cycles induction

+ zoom

BASELINE




CT | target liver lesion

WEEK 6



27% reduction vs baseline

WEEK 84



45% reduction vs baseline



06.2018
Patient had PR and remains on study treatment

CYCLE 45
TECENTRIQ
+ AVASTIN
Maintenance

30
MONTHS
PR



Patient safety summary

Treatment-related* AEs
all Grade 1-2

Constipation

Weight decrease

Stomatitis

Hyperthyroidism

Dry skin

Asthenia

Skin lesion
unknown diagnosis

*In opinion of investigator.
Treatment relationship may be
to one or more of atezolizumab,
bevacizumab, carboplatin or
paclitaxel.


No grade 3-4 AEs
No SAEs



TECENTRIQ + Avastin + carbo/pac for chemotherapy-naïve non-squamous mNSCLC

A powerful regimen when patients need more

Deliver sustained survival in specific patient types^{1,5}



TECENTRIQ + Avastin + carbo/pac nearly doubled PFS benefit at 12 months³

- 12 months PFS was 38% with TECENTRIQ + Avastin + carbo/pac vs 20% with Avastin + carbo/pac alone (HR=0.59; 95% CI, 0.50, 0.69; P<0.0001)

A majority of patients responded to TECENTRIQ + Avastin + carbo/pac³

- ORR 56% (95% CI, 51.4, 61.4) with TECENTRIQ + Avastin + carbo/pac vs 41% (95% CI, 35.3, 45.2) with Avastin + carbo/pac alone

A manageable and familiar safety profile³

- 2.0% of patients experienced ≥ grade 3 bleeding events with TECENTRIQ + Avastin + carbo/pac vs 1.3% with Avastin + carbo/pac alone†

The first cancer immunotherapy combination to demonstrate meaningful OS in EGFR+ patients and patients with liver metastases*



References

1. Tecentriq India prescribing Information 2. Avastin India prescribing Information 3. Socinski MA, Jotte R, Cappuzzo F, et al; IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288-2301. 4. Data on file. Roche. 5. Nogami N et. al J Thorac Oncol. 2022 Feb;17(2):309-323.

® = Registered Trade Mark F. Hoffmann - La Roche Limited, Basel, Switzerland.

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only.

Full prescribing information available on request.

For scientific information on Roche Medicinal Product please write to india.medinfo@roche.com

For all Adverse Events/Special Situation Reports with Roche Medicinal

Product please report the same to india.drugsafety@roche.com within one business day/24 hours.



http://bit.ly/Roche_Tecentriq_Avastin_PI

Please use the QR code/click on the link for the latest Prescribing Information (PI)



Roche Products (India) Pvt. Ltd,
146-B, 166 A, Unit No. 7, 8, 9,
8th Floor, R City Office, R City Mall,
Lal Bahadur Shastri Marg,
Ghatkopar, Mumbai - 400 086.
Maharashtra, India
Tel No. +91 22 50457300; Fax No, +91 22 50457301

M-IN-00002964
Expiration Date: 08/07/2024

 **TECENTRIQ**[®]
atezolizumab